Trial Profile
A pilot phase II study to determine the safety and efficacy of the combination of ONTAK (DAB389IL-2) [denileukin diftitox] with CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] in peripheral T-cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- 09 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record (NCT00337987).
- 09 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record (NCT00337987).
- 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.